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Recently however, improvements in survival have been described as a result of technological advances and experimental investigation. Automated external defibrillators permit very early defibrillation and have led to improved out-of-hospital survival. 7 Since the release of the 2005 AHA guidelines 8 emphasizing compressions to improve cardiac output, modest improvements in survival have been documented. 9, 10 Greater survival has been noted with therapeutic hypothermia in the post cardiac arrest period. 11, 12 But despite these improvements, substantial increases in survival have not been observed.
In this issue of Circulation, Reynolds et al 13 suggest that novel therapies should be evaluated earlier in the resuscitative efforts rather than after failure of prolonged traditional efforts. Using their local database developed from participation in the Resuscitation Outcomes Consortium Epistry 14 , they examined survival to discharge from hospital stratified by functional outcomes relative to CPR duration. Favorable outcome was defined by modified Rankin score (mRS) of 0 (no disability) to 3 (moderate disability, but able to walk unassisted). Patients were also classified as unfavorable status (mRS 4-5, moderately severe to severe disability), ROSC without survival to hospital discharge and no ROSC (RS 6). CPR quality was measured by thoracic impedance or by an accelerometer placed on the patient's chest. The time period studied, 2005-2011, coincides with the introduction and adoption of the 2005 guidelines emphasizing chest compressions and minimizing ventilations. Two models were constructed, one adjusted for prehospital covariates and the second adjusted for therapeutic hypothermia and cardiac catheterization. For those patients discharged with a mRS of 0-3, 90% had CPR durations of < 16 minutes, for those discharged with mRS 4-5, CPR duration was 23 minutes and mRS 6 was down (from 6% to 2% survival) with a 0.5% decline in survival for each minute of CPR (my visual estimates of Figure 3 ). After 15 minutes of CPR duration, survival is 2% and remains unchanged thereafter. Adjusting for both pre-hospital and inpatient covariates, CPR duration was independently associated with favorable functional status at hospital discharge. Importantly, even after controlling for therapeutic hypothermia and cardiac catheterization, CPR duration remained an independent predictor of death or disability. The data they present are not new nor unexpected. Probability of survival to hospital discharge after out-of-hospital cardiac arrest with a mRS <3 declines rapidly with each minute of CPR. Current CPR strategies are effective in the initial 15 minutes and after that, are unproductive and often futile. The authors propose that novel therapies be implemented early in the resuscitation while meaningful survival is still possible.
These conclusions are somewhat in contrast to a related analysis recently published in Circulation comparing CPR duration to outcomes of pediatric in-hospital cardiac arrest using the in-hospital Get With the Guidelines-Resuscitation database. 15 Median duration of CPR for survivors was 10 minutes and non-survivors 25 minutes, although, the proportion of survivors who received > 25-30 minutes of CPR is higher, especially for post-operative cardiac patients.
The probability of a favorable outcome for all patients was < 20% at CPR durations of 20 minutes and declined to 10% at 40 minutes (visual assessment of Fig 2) . However, the percentage of survivors to hospital discharge with good neurologic outcome following CPR durations of > 35 minutes varied from 44 to 68%, depending on pre-arrest diagnosis. The authors concluded that CPR for > 20 minutes was not futile in selected pediatric patients. The obvious difference between these studies is the patient population: i.e. pediatric vs adult and in-hospital vs out-of-hospital. Yet a comparable adult study from the same in-patient database concluded that systematic increases in resuscitation duration could alter survival in a high-risk population. 16 In comparing these studies, one must remember that inpatient cardiac arrest is distinct from outof-hospital and comparisons are likely not warranted.
Yet thinking that we can increase CPR duration to improve survival misses the point that more of the same will not result in dramatically improved outcomes for the majority of patients.
Prolonged resuscitation clearly predicts a higher probability of death. The experimental design of adding a therapy late in the resuscitation when end-organ damage is likely has failed to produce any change in outcome. [17] [18] [19] The proposal of initiating investigational therapies early in the resuscitation has considerable merit. Do we wait to administer antibiotics until sepsis has occurred or when the infection is localized? Do we wait until metastatic disease is present before starting anti-cancer therapy? No. Any therapy is more likely to be effective when the process is not "widespread". Given that cardiac arrest in any setting has a poor prognosis, implementing new therapies early in the resuscitation is justified.
But, along with developing novel therapies and an earlier paradigm for testing them, we need to consider additional investigative methods to the standard of randomized controlled trial.
Successful treatment of cardiac arrest requires a complex algorithm with integrated systems of care and it is difficult for single investigators or single sites to conduct these trials. The Anecdotal reports and studies showing some good survival after prolonged resuscitation attempts are not evidence that prolonged CPR is adequate.. The majority of patients have poor outcomes after 15 minutes. Rather, these unusual outcomes tell us there is more we don't know and force us to ask what is different. Innovative thinking and experimental designs exploiting those differences to develop novel therapies may provide better resuscitation for all. Caution is warranted when developing TOR guidelines, especially for in hospital cardiac arrest, and the algorithms need to be continually re-evaluated in the light of new information. But, we critically need innovative hypotheses and therapies and experimental paradigms to test them before we can expect different results. 
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